Accelerating Medical Treatments for Serious Mental Illness

Enumerated powers · passes

The order relies on federal authority over interstate commerce (Article I, Section 8, Clause 3) and the power to regulate drugs under the Food, Drug, and Cosmetic Act and Controlled Substances Act. The FDA's role in drug approval and the DEA's scheduling authority are well-established federal functions. The order does not exceed these enumerated powers.

Bill of Rights · passes

The order does not restrict speech, religion, assembly, press, petition, arms, quartering, search and seizure, self-incrimination, due process, takings, fair trial, jury, cruel and unusual punishment, or unenumerated rights. It expands access to medical treatments, which aligns with individual liberty. No infringement of the first ten amendments is present.

Individual liberty · passes

The order facilitates individual access to potentially life-saving treatments under the Right to Try Act, respecting personal autonomy in medical decisions. It does not restrict what individuals can do with their person, property, speech, labor, or belief. The burden of justification is met by the compelling interest in reducing suicide and serious mental illness.

Decentralization · raises concerns · severity: minor

While the order allows states to develop their own programs and provides federal support, it consolidates decision-making at the federal level by directing FDA prioritization, DEA rescheduling, and federal funding allocation. An individual or family cannot independently access Schedule I psychedelics without federal law changes, and local communities cannot override federal drug scheduling. The state can handle some aspects, but the federal role is necessary for interstate drug regulation. The order fails the fourth question because it consolidates upward the authority to accelerate drug approvals and rescheduling, which could be handled at lower levels with less federal involvement.

Due process and takings · passes

The order does not bypass due process or take property without just compensation. It operates within existing statutory frameworks (Right to Try Act, Controlled Substances Act, FDA approval processes) that provide procedural safeguards. The rescheduling review under 21 U.S.C. 811 includes notice and comment, ensuring fair process. No arbitrary government action or deprivation of property is involved.